BioNTech Reports Topline Data from P-II Study of BNT111 to Treat Advanced Melanoma Patients
Shots:
- The P-II Study assessed BNT111 + Libtayo (cemiplimab) as a combination and two single agents alone to treat unresectable stage III/IV, anti-PD-L-1 progressed melanoma patients
- The study reached its 1EPs, demonstrating improved ORR in patients treated with BNT111 + cemiplimab or cemiplimab monotx.; both montx. arms displayed clinical activity. The combination is well tolerated and safe. 2Eps are planned to assess further (not mature at primary analysis)
- BNT111 is a mRNA-based off-the-shelf cancer immunotherapy developed on BioNTech’s FixVac platform and proprietary uridine mRNA-LPX technology
Ref: BioNTech | Image: BioNTech
Related News: Triastek Partners with BioNTech to Develop 3D Printed Oral RNA Therapeutics
PharmaShots! Your go-to media platform for customized news ranging for multiple indications. For more information connect with us at connect@pharmashots.com
Click here to read the full press release
An avid reader and a dedicated learner, Prince works as a Content Writer at PharmaShots. Prince possesses an exceptional quality of breaking down the barriers of words by simplifying the terms in digestible chunks to make content readable and comprehensible. Prince likes to read books and loves to spend his free time learning and upskilling himself.
